Eyepoint Pharmaceuticals Inc (EYPT)

$17.08 -0.74 (-4.15%)
Market Cap 1.47B
Revenue (ttm) 43.27M
Net Income (ttm) -130.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -302.45%
Debt to Equity Ratio 0.00
Volume 1,429,818
Avg Vol 1,347,702
Day's Range N/A - N/A
Shares Out 82.79M
Stochastic %K 98%
Beta 1.67
Analysts Strong Sell
Price Target $34.00

Company Profile

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Duras...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 926 5000
Address:
480 Pleasant Street, Suite C-400, Watertown, United States
laaarsas
laaarsas Apr. 4 at 7:45 PM
$EYPT So I guess Ocular is most important competitor and are likely to have a better product. But that does not mean ph3 will not be a success.
0 · Reply
Sachi_Da
Sachi_Da Apr. 4 at 4:36 PM
$EYPT
1 · Reply
Toptradersam
Toptradersam Apr. 4 at 1:54 PM
$BYND $BCH $ELAB $EYPT 🤔 Could this be the next penny stock to run? Check out why I’m watching this one closely https://www.youtube.com/watch?v=caqYUiPKppU
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Apr. 4 at 12:52 AM
$EYPT Trading at $13.40, with average volume of 1,079,576, quite close to recent prices.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Apr. 4 at 12:06 AM
Comparing trending tickers $ETON vs $EYPT: ETON is down slightly by 1.46% at $24.99 with a trading volume of 472.3K shares, which is above its average of 344.6K. On the other hand, EYPT has climbed up by 2.92% to $13.40, with its volume also up at 1.2M, slightly higher than the normal 1.1M shares. EYPT is showing a more positive movement in both price and volume compared to ETON today.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Apr. 3 at 11:25 PM
not forcing trades on $EYPT need H% to drop like these examples
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Apr. 3 at 11:22 PM
$EYPT Trading around $13.40, volume at 1.15M, slightly higher than the average volume of 1.08M.
0 · Reply
Popeye_
Popeye_ Apr. 3 at 8:25 PM
$SNAP watchlist: $SNAP next triple digit stock in the making 🚀 Shareprice: $4.67 https://youtu.be/GnX3U5AMeAU?si=5CPWVC7Ks8I_-jyC $SBET Shareprice: $6.21 $BCH.X $ALGO.X $EYPT
0 · Reply
laaarsas
laaarsas Apr. 3 at 8:05 PM
$EYPT however Ocular seems to be proxy. They succeeded in ph3. Maybe that could mean EYPT also success
0 · Reply
laaarsas
laaarsas Apr. 3 at 7:46 PM
$EYPT ok population is way different in ph3 naive pts. Huge risk. Low bet or stay away.
0 · Reply
Latest News on EYPT
EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug

Mar 20, 2026, 5:24 PM EDT - 15 days ago

EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug

OCUL

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Mar 16, 2026, 7:00 AM EDT - 19 days ago

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint, Inc. (EYPT) Q4 2025 Earnings Call Transcript

Mar 4, 2026, 5:12 PM EST - 4 weeks ago

EyePoint, Inc. (EYPT) Q4 2025 Earnings Call Transcript

EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments

Mar 4, 2026, 7:00 AM EST - 4 weeks ago

EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments

EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema

Mar 2, 2026, 7:00 AM EST - 4 weeks ago

EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema

EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026

Feb 25, 2026, 7:00 AM EST - 5 weeks ago

EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026

EyePoint Announces Participation at Upcoming Investor Conferences

Feb 24, 2026, 7:00 AM EST - 5 weeks ago

EyePoint Announces Participation at Upcoming Investor Conferences

EyePoint Appoints Michael Campbell as Chief Commercial Officer

Feb 18, 2026, 7:00 AM EST - 6 weeks ago

EyePoint Appoints Michael Campbell as Chief Commercial Officer

EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Feb 5, 2026, 7:00 AM EST - 2 months ago

EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

EyePoint, Inc. (EYPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 2:26 PM EST - 2 months ago

EyePoint, Inc. (EYPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026

Jan 7, 2026, 7:00 AM EST - 3 months ago

EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026

EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 17, 2025, 7:00 AM EST - 3 months ago

EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference

EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

Nov 19, 2025, 7:00 AM EST - 4 months ago

EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

EyePoint Pharmaceuticals, Inc. (EYPT) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 2:31 PM EST - 5 months ago

EyePoint Pharmaceuticals, Inc. (EYPT) Q3 2025 Earnings Call Transcript

EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments

Nov 5, 2025, 7:00 AM EST - 5 months ago

EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments

EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025

Oct 29, 2025, 7:00 AM EDT - 5 months ago

EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025

EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal Study

Oct 15, 2025, 11:01 AM EDT - 6 months ago

EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal Study

EyePoint Announces Pricing of Public Offering

Oct 14, 2025, 10:43 PM EDT - 6 months ago

EyePoint Announces Pricing of Public Offering

EyePoint Announces Proposed Public Offering of Common Stock

Oct 14, 2025, 4:35 PM EDT - 6 months ago

EyePoint Announces Proposed Public Offering of Common Stock

EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema

Oct 14, 2025, 4:01 PM EDT - 6 months ago

EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema

EyePoint Pharmaceuticals, Inc. (EYPT) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 2, 2025, 6:03 PM EDT - 7 months ago

EyePoint Pharmaceuticals, Inc. (EYPT) Presents At Citi's Biopharma Back To School Conference Transcript

EyePoint Pharmaceuticals, Inc. (EYPT) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:09 PM EDT - 8 months ago

EyePoint Pharmaceuticals, Inc. (EYPT) Q2 2025 Earnings Call Transcript

EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 6, 2025, 7:30 AM EDT - 8 months ago

EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments

Aug 6, 2025, 7:00 AM EDT - 8 months ago

EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments

EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 30, 2025, 7:00 AM EDT - 8 months ago

EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025

EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

Jul 29, 2025, 7:00 AM EDT - 8 months ago

EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026

Jun 12, 2025, 11:03 AM EDT - 10 months ago

EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026

EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration

May 27, 2025, 7:00 AM EDT - 11 months ago

EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

May 16, 2025, 7:00 AM EDT - 11 months ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2025 Earnings Call Transcript

May 7, 2025, 2:49 PM EDT - 11 months ago

EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2025 Earnings Call Transcript

EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments

May 7, 2025, 7:00 AM EDT - 11 months ago

EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments

EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025

Apr 30, 2025, 7:00 AM EDT - 1 year ago

EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025

EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference

Mar 27, 2025, 7:00 AM EDT - 1 year ago

EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference

EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2024 Earnings Call Transcript

Mar 5, 2025, 2:51 PM EST - 1 year ago

EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2024 Earnings Call Transcript

EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments

Mar 5, 2025, 7:00 AM EST - 1 year ago

EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments

EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025

Feb 26, 2025, 7:00 AM EST - 1 year ago

EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025

EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference

Feb 25, 2025, 7:00 AM EST - 1 year ago

EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference

EyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea Rival

Jan 30, 2025, 12:39 PM EST - 1 year ago

EyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea Rival

EyePoint to Present at Guggenheim SMID Cap Biotech Conference

Jan 30, 2025, 7:00 AM EST - 1 year ago

EyePoint to Present at Guggenheim SMID Cap Biotech Conference

EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D.

Jan 8, 2025, 7:00 AM EST - 1 year ago

EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D.

EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration

Dec 4, 2024, 7:00 AM EST - 1 year ago

EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration

EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity

Nov 14, 2024, 5:04 AM EST - 1 year ago

EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Nov 4, 2024, 7:00 AM EST - 1 year ago

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

Oct 31, 2024, 4:00 PM EDT - 1 year ago

EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering

Oct 29, 2024, 9:47 PM EDT - 1 year ago

EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering

EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

Oct 28, 2024, 5:14 PM EDT - 1 year ago

EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema

Oct 28, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema

EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration

Oct 24, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration

EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors

Sep 4, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors

EyePoint Pharmaceuticals: After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)

Aug 29, 2024, 5:35 PM EDT - 1 year ago

EyePoint Pharmaceuticals: After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)

laaarsas
laaarsas Apr. 4 at 7:45 PM
$EYPT So I guess Ocular is most important competitor and are likely to have a better product. But that does not mean ph3 will not be a success.
0 · Reply
Sachi_Da
Sachi_Da Apr. 4 at 4:36 PM
$EYPT
1 · Reply
Toptradersam
Toptradersam Apr. 4 at 1:54 PM
$BYND $BCH $ELAB $EYPT 🤔 Could this be the next penny stock to run? Check out why I’m watching this one closely https://www.youtube.com/watch?v=caqYUiPKppU
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Apr. 4 at 12:52 AM
$EYPT Trading at $13.40, with average volume of 1,079,576, quite close to recent prices.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Apr. 4 at 12:06 AM
Comparing trending tickers $ETON vs $EYPT: ETON is down slightly by 1.46% at $24.99 with a trading volume of 472.3K shares, which is above its average of 344.6K. On the other hand, EYPT has climbed up by 2.92% to $13.40, with its volume also up at 1.2M, slightly higher than the normal 1.1M shares. EYPT is showing a more positive movement in both price and volume compared to ETON today.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Apr. 3 at 11:25 PM
not forcing trades on $EYPT need H% to drop like these examples
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Apr. 3 at 11:22 PM
$EYPT Trading around $13.40, volume at 1.15M, slightly higher than the average volume of 1.08M.
0 · Reply
Popeye_
Popeye_ Apr. 3 at 8:25 PM
$SNAP watchlist: $SNAP next triple digit stock in the making 🚀 Shareprice: $4.67 https://youtu.be/GnX3U5AMeAU?si=5CPWVC7Ks8I_-jyC $SBET Shareprice: $6.21 $BCH.X $ALGO.X $EYPT
0 · Reply
laaarsas
laaarsas Apr. 3 at 8:05 PM
$EYPT however Ocular seems to be proxy. They succeeded in ph3. Maybe that could mean EYPT also success
0 · Reply
laaarsas
laaarsas Apr. 3 at 7:46 PM
$EYPT ok population is way different in ph3 naive pts. Huge risk. Low bet or stay away.
0 · Reply
laaarsas
laaarsas Apr. 3 at 4:49 PM
$EYPT I’m having a hard time to see how ph3 will not be good and share price will rise significantly. Please help me see what I’m missing.
0 · Reply
laaarsas
laaarsas Apr. 3 at 4:11 PM
$EYPT why is short interest so high here? What’s the bear case? Catalyst coming up soon, why could one think ph3 will fail?
0 · Reply
laaarsas
laaarsas Apr. 2 at 12:52 PM
$EYPT hi all Egyptians. Seems like interesting case. What is vibe like here? What you think? What is biggest risks/problems you see? Preferably regarding ph3 readout regarding study design, statistical inference risk, changes from ph2 etc etc thanks!
0 · Reply
Poet5
Poet5 Mar. 31 at 1:20 PM
$EYPT Again, I should have taken all of it out went it hit 18.35 a few weeks ago. I am awaiting anticipated exceptional data in July/Aug. Unfortunately the market might out do 1929 by then. So 4.00?
0 · Reply
rizzato
rizzato Mar. 30 at 9:21 PM
$EYPT what a fuck? what is going on here?
0 · Reply
Dy2ski
Dy2ski Mar. 28 at 2:47 AM
$OCUL Besides the BS hitting the overall markets, in the last month $OCUL down 20%, $EYPT down 30%.
1 · Reply
Quantumup
Quantumup Mar. 27 at 12:44 PM
H.C. Wainwright reiterated $OCUL Buy/$21 $KOD $EYPT $REGN RHHBY $SRZN Here's what H.C. Wainwright had to say in its note: https://x.com/Quantumup1/status/2037510171836960935?s=20
0 · Reply
twib
twib Mar. 25 at 2:32 PM
$EYPT Well im hoping this will be start of uptrend but will be patient rhru results, added today and wlllbelow $15. Gl all
2 · Reply
rizzato
rizzato Mar. 25 at 1:51 PM
$EYPT he really spoke very well thanks
0 · Reply
rizzato
rizzato Mar. 25 at 12:08 PM
$EYPT let's see if they say something interesting today
0 · Reply
Jdliberty
Jdliberty Mar. 24 at 5:07 PM
$EYPT $EYPT After reviewing the complaint and exhibits, the dispute appears to center less on whether adverse events occurred and more on how the data was framed—specifically subset vs full dataset comparisons and, importantly, causation vs occurrence. Those distinctions can materially affect interpretation, and some independent commentary has raised similar questions. Ultimately, the Phase 3 readouts (LUGANO mid-year, LUCIA to follow) are the real inflection points and should provide the clearest resolution.
3 · Reply
Jdliberty
Jdliberty Mar. 24 at 4:27 PM
$EYPT Look at Exhibits A, B and C. Its a good positive narrative appropriately brought to light in the suit. Current downward pressure has more to do with Iran and larger market conditions imo.
0 · Reply